Parkinson's disease and appendix: a hidden kinship

Authors

  • Hetvi H. Patel Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  • Maitry H. Rathod Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  • Bisojeet R. Khandai Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  • Ami N. Vyas Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20261128

Keywords:

Parkinson’s disease, Vermiform appendix, α-synuclein, Gut–brain axis, Lewy bodies, Gastrointestinal involvement

Abstract

Parkinson’s disease is now recognized as the second most prevalent neurodegenerative disorder after Alzheimer’s disease. More than 8.5 million people worldwide are estimated to have Parkinson’s, and its frequency is rising swiftly because of global population aging. The disease is primarily marked by abnormal protein clumps, called Lewy bodies, found in the brain. Numerous studies have connected Parkinson’s disease to the gut, suggesting that gastrointestinal issues like appendicitis could increase the likelihood of developing Parkinson’s later in life. A review of several studies on the link between Parkinson’s disease and gastrointestinal disorders shows that Parkinson’s often follows such disorders, though genetics, the environment, and an individual’s immune system also contribute. Some studies, however, report that early appendectomy may lower the risk of Parkinson’s or delay its onset in people with a family history of the disease. This review examines the evidence on the relationship between the appendix and Parkinson’s disease, presenting data on how the appendix may influence the development of PD. We conclude that while the appendix is not the only factor in Parkinson’s disease, it may play an important role in its development.

References

Bollinger RR, Barbas AS, Bush EL, Lin SS, Parker W. Biofilms in the large bowel suggest an apparent function of the human vermiform appendix. J Theor Biol. 2007;249(4):826-31.

West AB, Maidment NT. Parkin and Parkinson’s disease. Curr Opin Neurol. 2001;14(4):477-82.

Auburger G, Klinkenberg M, Drost J, Marcus K, Morales-Gordo B, Kunz WS, et al. Primary skin fibroblasts as a model of Parkinson’s Disease. Mol Neurobiol. 2012;46(1):20-7.

Warnecke T, Schäfer KH, Claus I, Del Tredici K, Jost WH. Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management. npj Parkinsons Dis. 2016;2:16024.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591-601.

Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological alpha-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016;79:940-9.

GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939-53.

Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors. Nat Rev Neurol. 2015;11:625-36.

Smith HF, P W, SH K, M L. Morphological evolution of the mammalian cecum and cecal appendix. CR Palevol. 2017;16:39-57.

Vitetta L, Chen J, Clarke S. The vermiform appendix: An immunological organ sustaining a microbiome inoculum. Clin Sci (Lond). 2019;133:1-8.

Palestrant D, Holzknecht ZE, Collins BH, Parker W, Miller SE, Bollinger RR. Microbial biofilms in the gut: Visualization by electron microscopy and by acridine orange staining. Ultrastruct Pathol. 2004;28: 23-7.

Masahata K, Umemoto E, Kayama H, Kotani M, Nakamura S, Kurakawa T, et al. Generation of colonic IgA-secreting cells in the caecal patch. Nat Commun. 2014;5:3704.

Killinger BA, Madaj Z, Sikora JW, Rey N, Haas AJ, Vepa Y, et al. The vermiform appendix impacts the risk of developing Parkinson’s disease. Sci Transl Med. 2018;10:eaar5280.

Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci. 2014; 34:9441-54.

Kellie JF, Higgs RE, Ryder JW, Major A, Beach TG, Adler CH, et al. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson’s disease brain tissue by intact protein mass spectrometry. Sci Rep. 2014;4:5797.

Grassi D, Howard S, Zhou M, Diaz-Perez N, Urban NT, Guerrero-Given D, et al. Identification of a highly neurotoxic alpha-synuclein species inducing mitochondrial damage and mitophagy in Parkinson’s disease. Proc Natl Acad Sci U S A. 2018;115: E2634-43.

Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci. 2010; 32:409-22.

Luk KC, Song C, O’Brien P, Stieber A, Branch JR, Brunden KR, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009;106:20051-6.

Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem. 2001;276:2380-6.

Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson’s disease-linked mutations. Proc Natl Acad Sci U S A. 2005;102:2162-7.

Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, et al. Role of alpha-synuclein carboxy-terminus on fibril formationin vitro. Biochemistry. 2003;42:8530-40.

Mendes A, Goncalves A, Vila-Cha N, Moreira I, Fernandes J, Damasio J, et al. Appendectomy may delay Parkinson’s disease onset. Mov Disord. 2015; 30:1404-7.

Yilmaz R, Bayram E, Ulukan C, Altinok MK, Akbostanci MC. Appendectomy history is not related to Parkinson’s disease. J Parkinsons Dis. 2017;7: 347-52.

Marras C, Lang AE, Austin PC, Lau C, Urbach DR. Appendectomy in mid and later life and risk of Parkinson’s disease: A population-based study. Mov Disord. 2016;31:1243-7.

Svensson E, Horvath-Puho E, Stokholm MG, Sorensen HT, Henderson VW, Borghammer P. Appendectomy and risk of Parkinson’s disease: A nationwide cohort study with more than 10 years of follow-up. Mov Disord. 2016;31:1918-22.

Killinger BA, Madaj Z, Sikora JW, Rey N, Haas AJ, Vepa Y, et al. The vermiform appendix impacts the risk of developing Parkinson’s disease. Sci Transl Med. 2018;10:eaar5280.

Downloads

Published

2026-04-22

How to Cite

Patel, H. H., Rathod, M. H., Khandai, B. R., & Vyas, A. N. (2026). Parkinson’s disease and appendix: a hidden kinship . International Journal of Basic & Clinical Pharmacology, 15(3), 578–581. https://doi.org/10.18203/2319-2003.ijbcp20261128

Issue

Section

Review Articles